World Ovarian Cancer Day

Observed on May 8, World Ovarian Cancer Day 2025 carries the theme “No Woman Left Behind,” reinforcing the urgent need to close the gaps in access, diagnosis, treatment, and care across all regions and socioeconomic groups. Ovarian cancer remains one of the deadliest gynecological cancers, often detected too late due to vague symptoms and limited screening tools. The World Ovarian Cancer Coalition projects a 55% rise in annual cases and nearly 70% more deaths by 2050, with the heaviest burden falling on low- and middle-income countries. Equitable access to early diagnostics, genetic testing, and targeted therapies is critical. As per IMARC projections, the global ovarian cancer market size reached USD 2.3 Billion in 2024 and is expected to grow to USD 5.5 Billion by 2033, with a CAGR of 9.59% from 2025-2033. From AI-enhanced blood tests to cutting-edge antibody-drug conjugates, innovation is expanding hope.

A Silent Surge: Global Incidence on the Rise

Ovarian cancer, often referred to as the "silent killer," continues to pose a significant health challenge worldwide. The World Cancer Research Fund reports that it is the 18th most frequently diagnosed cancer worldwide and the 8th most prevalent cancer among women. In 2022, an estimated 324,603 women worldwide were diagnosed with ovarian cancer. If current trends continue unchecked, this number will rise to nearly 500,000 annually by 2050, a 55% increase. The most significant rise in absolute numbers will occur in Asia, while Africa is projected to see the highest percentage jump, more than doubling its current incidence. Deaths from the disease are also set to soar from 206,956 to over 350,000 annually by 2050, with Africa and Asia bearing the heaviest burden.

Sharper Tools: Diagnostic Breakthroughs

Advancements in diagnostic technologies are enhancing the early detection of ovarian cancer:

The Raman detection method focuses on identifying haptoglobin, a biomarker associated with epithelial ovarian cancer. This technique has demonstrated a diagnostic sensitivity of 100% and specificity of 85%, indicating its potential as a reliable diagnostic tool.
Introduced at the ESGO 2025 Annual Meeting, the "Vienna Index" and "Top Vienna Index" are advanced diagnostic tools that incorporate age into existing biomarker combinations. These indices aim to improve the differentiation of adnexal masses, thereby enhancing the accuracy of ovarian cancer detection.
A clinical trial led by the University of Queensland is evaluating a blood test that detects early-stage ovarian cancer by targeting extracellular vesicles (EVs). Preliminary studies have shown this test to have an overall accuracy of 94% and a low false positive rate of 4%, making it a promising tool for early detection.

Targeted Strikes: Therapies in the Pipeline

The therapeutic landscape for ovarian cancer is evolving with promising developments:

ELAHERE (mirvetuximab soravtansine-gynx) is an antibody-drug conjugate designed to treat platinum-resistant ovarian cancer that expresses folate receptor alpha (FRα). In the final results from the Phase 3 MIRASOL trial, which had a median follow-up period of 30.5 months, the drug showed a 32% lower risk of death compared to standard chemotherapy. Patients receiving ELAHERE also experienced a greater objective response rate and longer median overall survival.
Cartherics is set to begin clinical trials in 2025 for CTH-401, an investigational allogeneic (off-the-shelf) CAR-NK cell therapy specifically developed to target ovarian cancer. Derived from a clonal induced pluripotent stem cell (iPSC) master bank, CTH-401 is genetically engineered with a second-generation CAR construct aimed at tumor-associated glycoprotein-72 (TAG-72), a known marker in solid tumors. The therapy incorporates dual gene deletions to counter immunosuppression, enhancing persistence and long-term efficacy.
In May 2024, Genmab A/S, a Danish biotechnology company, completed its acquisition of ProfoundBio, Inc., a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs) and ADC technologies for cancer treatment. The all-cash transaction, valued at USD 1.8 Billion, grants Genmab worldwide rights to ProfoundBio's portfolio, including three clinical candidates and several preclinical programs.

Voices Amplified: Awareness and Screening Initiatives

Awareness and early detection are crucial in combating ovarian cancer:

AI-integrated blood tests are emerging as a breakthrough in early-stage ovarian cancer detection, reinforcing the impact of awareness campaigns that emphasize timely screening and symptom recognition. For instance, in May 2025, AOA Dx's AI-driven blood test for ovarian cancer demonstrated over 90% accuracy in detecting early-stage disease in a study involving approximately 1,000 symptomatic women. The test integrates lipid, ganglioside, and protein biomarkers analyzed through machine learning, offering a promising tool for earlier diagnosis and improved patient outcomes.
September is recognized as Ovarian Cancer Awareness Month. This month-long observance brings together medical professionals, researchers, advocates, and communities worldwide to focus on transforming ovarian cancer outcomes through coordinated action.
The Ovarian Cancer Control Initiative (OCCI) and Johanna’s Law are educational programs aimed at increasing awareness and promoting early detection of ovarian cancer. OCCI, established by the CDC, coordinates health activities to increase early detection and awareness. Johanna’s Law, officially known as the Gynecologic Cancer Education and Awareness Act, supports national campaigns to educate women about the risks and symptoms of gynecologic cancers.

Backing the Battle: Investment and Funding Momentum

Investment in ovarian cancer research and treatment is gaining momentum:

In March 2025, the Ovarian Cancer Research Alliance (OCRA) announced an allocation of over USD 6 Million for research projects commencing in 2025. These funds are directed toward addressing critical challenges in ovarian cancer, including recurrence, treatment resistance, and disparities in patient outcomes.
In 2025, women founders and co-founders in the US secured approximately 22.8% of all venture capital funding, totaling around USD 34.4 Billion.
The US Department of Defense's Ovarian Cancer Research Program received funding of USD 15 Million to support patient-centered research aimed at preventing, detecting, treating, and curing ovarian cancer.

IMARC’s Role: Empowering Action against Ovarian Cancer

IMARC Group equips stakeholders across the healthcare ecosystem with the strategic intelligence needed to address the global burden of ovarian cancer. Our services enable clients to uncover opportunities, minimize challenges, and advance innovation in ovarian cancer detection, treatment, and care through:

Disease Insights: Analyze global ovarian cancer incidence, mortality patterns, and critical gaps in early diagnosis, targeted therapies, and survivorship support across diverse populations.
Future Preparedness: Monitor developments in genetic screening, AI-enabled diagnostic imaging, and personalized treatment approaches to shape long-term care strategies.
Innovation Tracking: Follow clinical trial progress, therapeutic advancements in CAR-T and immunotherapies, and integration of digital platforms improving patient navigation and care coordination.
Policy & Access Review: Assess how national screening programs, public health campaigns, and evolving reimbursement policies are influencing timely diagnosis and equitable access to care.
Customized Advisory Services: From early pipeline assessments to awareness campaign design, we offer tailored guidance to strengthen your impact on ovarian cancer outcomes.

From R&D to reimbursement, IMARC equips investors, researchers, and public health agencies with the data they need to drive real outcomes in ovarian cancer prevention, detection, and care. We help transform awareness into impact globally.

A Call to Contribute: From Awareness to Action

World Ovarian Cancer Day 2025 is more than a date. It’s a global reminder of what’s still at stake. With diagnostic breakthroughs, expanding treatment pipelines, and rising awareness, we have powerful tools in hand. But progress hinges on long-term funding, cross-sector collaboration, and stronger global health systems. Reducing the toll of ovarian cancer is not just a healthcare priority, it’s a matter of equity and survival.

Silence enables the continued spread and impact of this disease, which is why raising our voices and efforts matters now more than ever. Let’s amplify the effort.

Let’s make 2025 a turning point for ovarian cancer!

Request a Callback

Factory Setup Services

IMARC Group's factory setup services streamline the entire establishment process, ensuring efficient planning, seamless execution, and optimal operational readiness for your manufacturing facility.

Site Selection Services

IMARC Group's site selection services optimize location choices for businesses, ensuring strategic, cost-effective, and efficient manufacturing operations.

Engineering and Design Services

IMARC Group's factory engineering and design services deliver efficient and customized solutions to enhance operational performance and optimize production processes.

Factory Audit Services

IMARC Group's plant audit services offer comprehensive evaluations of your industrial facility's health, efficiency, and regulatory compliance.

Regulatory Approvals, and Licensing Services

IMARC Group's regulatory approval and licensing services ensure businesses meet all compliance requirements, facilitating smooth and timely market entry.

Partner Identification

IMARC Group's partner identification services help businesses find the ideal distributor, machinery supplier, raw material provider, or contract manufacturer, enhancing operational efficiency and growth.

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.

Our Clients

}

Contact Us

Have a question or need assistance? Please complete the form with your inquiry or reach out by emailing us on sales@imarcgroup.com.

Full Name *

Email *

Phone Number *

Country *

Message*

Please enter the Captcha text*

World Asthma Day 2025: Strengthening Global Awareness and Response

In clinics around the world, a concerning pattern is becoming increasingly evident: a growing number of patients are experiencing wheezing, breathlessness, and persistent coughing. This surge reflects a broader global trend. According to the World Health Organization (WHO), more than 260 million people are currently living with asthma, making it one of the most widespread and persistent chronic respiratory conditions globally.

World Malaria Day 2025: A Turning Point in Global Immunization

Observed on April 25, World Malaria Day 2025 carries the theme “Accelerating Equity in Malaria Prevention and Cure,” underscoring the urgent need to reach communities still lacking access to life-saving vaccines and diagnostics. While global malaria death rates have seen modest declines, the disease continues to claim the life of one child every minute, highlighting the critical need for swift, equity-driven action

Profitability and Cost Analysis of Sulfamethoxazole Manufacturing Plant: A Cost Model Approach

Sulfamethoxazole is a common synthetic antibacterial that is a member of the sulfonamide class of antibiotics. This substance plays a very significant role in modern medicine due to the amazing capabilities offered by the substance for curing infections and bacterial diseases. Trimethoprim and sulfamethoxazole are frequently used together to create the well-known antibiotic co-trimoxazole, which is well-known for its potency against a variety of bacterial infections. It works by preventing the manufacture of folic acid, which is necessary for the growth of bacteria. Sulfamethoxazole is an essential part of modern antibiotic therapy since it has been used to treat lung infections, urinary tract infections, and other common bacterial illnesses.

Capital and Operational Cost Model of Healthcare Consumables Manufacturing Plant: A Detailed Cost Model

Healthcare consumables are necessary medical supplies used for patient treatment, diagnostics, and cleanliness in clinics, hospitals, and home care settings. These consist of supplies such as surgical masks, bandages, gloves, syringes, catheters, and disinfectants. Usually, they are disposable or single use to preserve sterility and stop infections. Healthcare consumables are an essential component of the global healthcare ecosystem and are in high demand due to expanding healthcare needs, an increase in operations, infection control measures, and technological improvements.

Optimizing Catheter Production: A Comprehensive Cost Analysis

Catheters are flexible, tubular medical devices designed to access various body cavities, organs, or blood vessels for diagnostic or therapeutic purposes. They can be broadly classified into types based on their application, including urinary catheters, cardiac catheters, and intravenous (IV) catheters. Catheters are commonly used in diverse healthcare settings for managing chronic conditions, enabling fluid drainage, delivering medications, or facilitating minimally invasive surgeries.

Bioinformatics: Unlocking the Secrets of the Genome

Bioinformatics involves applying computational techniques and tools to study and understand biological systems at the molecular level. It is a field of study that combines mathematics, biology, computer science, and statistics to research genomic data and biological networks. The goal is to interpret information from large biological data sets, such as DNA sequences, protein structures, gene expressions, and other high-throughput experimental data. This field provides various products and services, such as knowledge management tools, bioinformatics platforms, and services.

Australia's Roadmap to Excellence: Non-Animal Models at the Forefront of Medical Progress

A non-animal model refers to an experimental system or method used in scientific research or testing that does not involve the use of animals. These models are developed to simulate biological processes, test hypotheses, or study diseases without the need for live animals. The aim is often to reduce the reliance on animal testing, which has ethical implications and raises concerns about animal welfare.

Revolutionizing Medicine: FDA Explores Innovations to Propel Cell and Gene Therapy Advancements

Cell therapy involves the transplantation and manipulation of living cells to replace and repair damaged tissue. Its primary branches include stem cell therapy and non-stem cell therapy. Stem cell therapy utilizes stem cells to repair, replace, or rejuvenate damaged or diseased cells and tissues as they possess the ability to differentiate into various specialized cell types, making them valuable for regenerative medicine. Non-stem cell-based therapies typically involve somatic cells isolated from the human body. These cells are propagated, expanded, selected, and then administered to patients for curative, preventive, or diagnostic purposes. On the other hand, gene therapy seeks to treat diseases by introducing, replacing, or inactivating genes within cells.